CL2017000957A1 - Formas de dosificación oral de magnesio de liberación controlada, de alta carga y métodos para elaborar y utilizar las mismas - Google Patents

Formas de dosificación oral de magnesio de liberación controlada, de alta carga y métodos para elaborar y utilizar las mismas

Info

Publication number
CL2017000957A1
CL2017000957A1 CL2017000957A CL2017000957A CL2017000957A1 CL 2017000957 A1 CL2017000957 A1 CL 2017000957A1 CL 2017000957 A CL2017000957 A CL 2017000957A CL 2017000957 A CL2017000957 A CL 2017000957A CL 2017000957 A1 CL2017000957 A1 CL 2017000957A1
Authority
CL
Chile
Prior art keywords
dosage forms
controlled release
develop
methods
oral dosage
Prior art date
Application number
CL2017000957A
Other languages
English (en)
Inventor
Sthephen F Brandon
Richard A Okerholm
Thomas J Legg
Original Assignee
Pharmalyte Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58578872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000957(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US15/132,461 external-priority patent/US9707253B2/en
Application filed by Pharmalyte Solutions Llc filed Critical Pharmalyte Solutions Llc
Publication of CL2017000957A1 publication Critical patent/CL2017000957A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>FORMAS DE DOSIFICACIÓN DE ALTA CARGA ORAL DE SAL LACTATO DE MAGNESIO DE LIBERACIÓN CONTROLADA.</p>
CL2017000957A 2016-04-19 2017-04-18 Formas de dosificación oral de magnesio de liberación controlada, de alta carga y métodos para elaborar y utilizar las mismas CL2017000957A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15/132,461 US9707253B2 (en) 2008-05-19 2016-04-19 High-loading, controlled-release magnesium oral dosage forms and methods for making and using same

Publications (1)

Publication Number Publication Date
CL2017000957A1 true CL2017000957A1 (es) 2017-12-15

Family

ID=58578872

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000957A CL2017000957A1 (es) 2016-04-19 2017-04-18 Formas de dosificación oral de magnesio de liberación controlada, de alta carga y métodos para elaborar y utilizar las mismas

Country Status (12)

Country Link
EP (1) EP3243507A1 (es)
JP (1) JP2017214352A (es)
KR (1) KR20170119651A (es)
AR (1) AR108235A1 (es)
AU (1) AU2017202534B1 (es)
CA (1) CA2964581C (es)
CL (1) CL2017000957A1 (es)
MX (1) MX2017005042A (es)
MY (1) MY185460A (es)
RU (1) RU2017113518A (es)
SG (1) SG10201703206TA (es)
ZA (1) ZA201702773B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212149A1 (en) 2022-01-18 2023-07-19 Rijksuniversiteit Groningen Oral dosage forms of acid-labile salt and methods and uses related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002774A (en) * 1989-06-08 1991-03-26 Erbamont, Inc. Sustained release pharmaceutical tablet
CN102098921A (zh) * 2008-05-19 2011-06-15 温顿制药有限公司 高载量、控释镁口服制剂及其制备和使用方法

Also Published As

Publication number Publication date
EP3243507A1 (en) 2017-11-15
AU2017202534B1 (en) 2017-06-08
CA2964581A1 (en) 2017-10-19
SG10201703206TA (en) 2017-11-29
KR20170119651A (ko) 2017-10-27
RU2017113518A (ru) 2018-10-19
CA2964581C (en) 2020-06-16
MX2017005042A (es) 2018-08-20
AR108235A1 (es) 2018-08-01
MY185460A (en) 2021-05-19
JP2017214352A (ja) 2017-12-07
ZA201702773B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016001963A1 (es) Heteroarilos inhibidores de syk
TWD179502S (zh) 相機
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CR20170100A (es) Indazoles sustituidos con bencilo como inhibidores bub1
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
UY34651A (es) ?formas de dosificación de liberación inmediata resistentes a la manipulación, procesos para prepararlas, métodos y usos de las mismas?..
EA201790273A1 (ru) Флагеллиновые композиции и их применение
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
DOP2016000253A (es) Nuevos compuestos
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
CL2018000621A1 (es) Ciano tienotriazolpirazinas y usos de las mismas solicitudes relacionadas.
ECSP14030779A (es) Inhibidores del nampt
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
CL2017002689A1 (es) Derivados de pirrolidincarboxamido y métodos para prepararlos y usarlos
CO2017005732A2 (es) Compuestos de dihidropirimidin-2-ona y sus usos médicos
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo